217 related articles for article (PubMed ID: 38554170)
1. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
Nagai S; Ozawa K
Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.
Lalhmangaihzuala S; Vanlaldinpuia K; Khiangte V; Laldinpuii Z; Liana T; Lalhriatpuia C; Pachuau Z
Mol Divers; 2024 Mar; ():. PubMed ID: 38554170
[TBL] [Abstract][Full Text] [Related]
3. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
[TBL] [Abstract][Full Text] [Related]
5. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
6. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
[TBL] [Abstract][Full Text] [Related]
8. Carbohydrate-based drugs launched during 2000
Cao X; Du X; Jiao H; An Q; Chen R; Fang P; Wang J; Yu B
Acta Pharm Sin B; 2022 Oct; 12(10):3783-3821. PubMed ID: 36213536
[TBL] [Abstract][Full Text] [Related]
9. The Current Directions of Searching for Antiparasitic Drugs.
Dziduch K; Greniuk D; Wujec M
Molecules; 2022 Feb; 27(5):. PubMed ID: 35268635
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q
Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924
[TBL] [Abstract][Full Text] [Related]
11. Another Monoclonal Antibody Granted EUA to treat COVID-19.
Aschenbrenner DS
Am J Nurs; 2021 Aug; 121(8):22. PubMed ID: 34819468
[TBL] [Abstract][Full Text] [Related]
12. Miglustat Therapy for
Quraishi IH; Szekely AM; Shirali AC; Mistry PK; Hirsch LJ
Neurol Genet; 2021 Oct; 7(5):e614. PubMed ID: 34337151
[TBL] [Abstract][Full Text] [Related]
13. [Advances in metabolic engineering of macrolide antibiotics].
Hao T; He W
Sheng Wu Gong Cheng Xue Bao; 2021 May; 37(5):1737-1747. PubMed ID: 34085452
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine.
Qiu M; Huang S; Luo C; Wu Z; Liang B; Huang H; Ci Z; Zhang D; Han L; Lin J
Biomed Pharmacother; 2021 Jul; 139():111561. PubMed ID: 33848775
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
